The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Mature results of the GETUG 13 phase III trial in poor-prognosis germ-cell tumors (GCT).
 
Karim Fizazi
Honoraria - Astellas Pharma; Janssen; Sanofi; Takeda
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Curevac; ESSA; Janssen Oncology; Novartis; Orion; Roche/Genentech; Sanofi
Travel, Accommodations, Expenses - Amgen
 
Aude Flechon
No Relationships to Disclose
 
Gwenael / Le Teuff
No Relationships to Disclose
 
Jozef Mardiak
No Relationships to Disclose
 
Lance C. Pagliaro
No Relationships to Disclose
 
Lionnel Geoffrois
No Relationships to Disclose
 
Pierre Kerbrat
No Relationships to Disclose
 
Christine Chevreau
No Relationships to Disclose
 
Remy Delva
No Relationships to Disclose
 
Frederic Rolland
No Relationships to Disclose
 
Christine Theodore
No Relationships to Disclose
 
Guilhem Roubaud
No Relationships to Disclose
 
Gwenaelle Gravis
No Relationships to Disclose
 
Jean-Christophe Eymard
No Relationships to Disclose
 
Jean-pierre Malhaire
No Relationships to Disclose
 
Claude Linassier
No Relationships to Disclose
 
Muriel Habibian
No Relationships to Disclose
 
Maria Reckova
No Relationships to Disclose
 
Christopher Logothetis
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Churchill Pharmaceuticals; Clovis Oncology; Helsinn Healthcare; Johnson & Johnson; Novartis; Pfizer; Sanofi
Research Funding - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Cougar Biotechnology; Exelixis; GlaxoSmithKline; Johnson & Johnson; Karyopharm Therapeutics; Novartis; Pfizer; Sanofi
 
Stephane Culine
No Relationships to Disclose